Manufacturers don’t use fast-track reimbursement in Europe. Although this seems like an oversight, there are six reasons explaining why it is not happening.
A strategic market access consultant won’t create a strategy for you but can help a great deal in optimal decision making and saving money down the road. Here are 5 reasons why you need one.
With its focus on value, a traditional Global Value Dossier reinforces a common pitfall in clinical development and commercialisation. This is the idea that if
Simply making essential cancer medicines more affordable does not guarantee that patients will receive the right medicine at the right time. Whilst essential cancer medicines are almost universally available in developed markets, what is industry currently doing to facilitate access to these medicines in LLMICs, who perhaps need it most?
Join Sarah, Associate Consultant at Inbeeo, as she works to solve exciting market access challenges for our global life sciences clients.
France’s Health Innovation 2030 Plan Proposes to Adopt a Market Access Pathway Like the German System to Accelerate Patient Access to Innovative Medicines – What Changes Can Be Expected?
Earlier this year, the UK government announced the Rare Diseases Framework, outlining strategy to improve the delivery of care to the 3.5 million people living within the four nations of the UK with a rare disorder.
All eyes were on pharma biotech companies in 2020, as they raced against each other to find solutions to alleviate the Covid-19 pandemic through vaccines and treatments.
Our CEO Herve Lillu recently led a discussion on this topic at the 2020 World Pharma pricing, Evidence, and Market Access Congress. Before we get
Many market access decisions were intended to provide rapid one-off answers to one of the most extraordinary situations healthcare systems have ever had to face, but some of them are telling us something about the more profound changes that are likely to affect pharmaceutical market access in the longer run.
